C WorldWide Group Holding A S raised its position in Cara Therapeutics, Inc. (NASDAQ:CARA) by 76.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 291,341 shares of the biopharmaceutical company’s stock after purchasing an additional 126,330 shares during the quarter. C WorldWide Group Holding A S owned 0.89% of Cara Therapeutics worth $3,988,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Gotham Asset Management LLC bought a new position in shares of Cara Therapeutics during the second quarter worth about $448,000. Vanguard Group Inc. grew its stake in Cara Therapeutics by 20.0% during the first quarter. Vanguard Group Inc. now owns 943,627 shares of the biopharmaceutical company’s stock worth $17,353,000 after purchasing an additional 156,958 shares during the period. Swiss National Bank acquired a new stake in Cara Therapeutics during the second quarter worth approximately $651,000. FMR LLC grew its stake in Cara Therapeutics by 27.7% during the second quarter. FMR LLC now owns 1,198,812 shares of the biopharmaceutical company’s stock worth $18,450,000 after purchasing an additional 260,036 shares during the period. Finally, Alliancebernstein L.P. grew its stake in Cara Therapeutics by 90.1% during the second quarter. Alliancebernstein L.P. now owns 38,600 shares of the biopharmaceutical company’s stock worth $594,000 after purchasing an additional 18,300 shares during the period. Hedge funds and other institutional investors own 61.03% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/11/13/c-worldwide-group-holding-a-s-boosts-holdings-in-cara-therapeutics-inc-cara.html.

In related news, CEO Derek T. Chalmers sold 16,000 shares of Cara Therapeutics stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $12.66, for a total transaction of $202,560.00. Following the transaction, the chief executive officer now owns 1,066,292 shares of the company’s stock, valued at $13,499,256.72. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 7.50% of the stock is owned by insiders.

Several equities research analysts recently commented on the company. Raymond James Financial, Inc. decreased their target price on Cara Therapeutics from $28.00 to $25.00 and set a “market perform” rating for the company in a research note on Thursday, August 3rd. Piper Jaffray Companies set a $27.00 target price on Cara Therapeutics and gave the stock a “buy” rating in a research note on Saturday, August 5th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Cara Therapeutics in a research note on Friday, August 4th. BidaskClub cut Cara Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 target price on shares of Cara Therapeutics in a research note on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. Cara Therapeutics presently has a consensus rating of “Buy” and an average price target of $25.17.

Shares of Cara Therapeutics, Inc. (CARA) traded up $0.17 during trading on Monday, reaching $13.43. The company’s stock had a trading volume of 145,078 shares, compared to its average volume of 1,874,505. Cara Therapeutics, Inc. has a 12-month low of $8.61 and a 12-month high of $28.50.

Cara Therapeutics (NASDAQ:CARA) last announced its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.03). During the same quarter in the previous year, the business earned ($0.42) earnings per share. equities research analysts expect that Cara Therapeutics, Inc. will post -1.84 EPS for the current fiscal year.

Cara Therapeutics Profile

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.

Want to see what other hedge funds are holding CARA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cara Therapeutics, Inc. (NASDAQ:CARA).

Institutional Ownership by Quarter for Cara Therapeutics (NASDAQ:CARA)

Receive News & Stock Ratings for Cara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc. and related stocks with our FREE daily email newsletter.